Neuropathy & Pain

Results of a meta-analysis indicate that the antiepileptic agent pregabalin is safe and effective for relieving pain in diabetic peripheral neuropathy (DPN).

Vitamin D insufficiency is under recognized and may be a significant contributor to neuropathic pain in type 2 diabetes. Vitamin D supplementation may be an effective “analgesic” in relieving neuropathic pain.

The indicator plaster neuropad (IPN) is a new test that can be used by diabetic patients to identify peripheral neuropathy, according to a new published report in the February issue of Diabetes Care.

Neurological evaluation of diabetics indicates that there is relationship between diminished vascular endothelial growth factor (VEGF) expression and neuropathy.

Smoked cannabis eased pain induced in healthy volunteers, according to a study by researchers at the University of California, San Diego (UCSD) Center for Medical Cannabis Research (CMCR.) However, the researchers found that less may be more.

Dr. Sheri Colberg, author of The 7 Step Diabetes Fitness Plan: Living Well and Being Fit with Diabetes, has more help for your patients who need exercise. Exercising with Complications: Neuropathy. This is a good one to print out add to your handouts.

Painful neuropathy is more common in patients with type 2 diabetes than in those with type 1, due to metabolic syndrome, researchers suggest, because of a link with the metabolic syndrome.

A major epidemiological study conducted over eight years in Australia has shown that two classes of lipid-lowering drugs – statins and fibrates – significantly lower the risk of developing nerve damage known as peripheral sensory diabetic neuropathy.

Patients with diabetic peripheral neuropathic pain (DPNP) who have more severe symptoms are more likely to respond to duloxetine.

Preliminary results from a phase III withdrawal-design trial with lacosamide in patients with painful diabetic neuropathy show that lacosamide was statistically significant over placebo in reducing pain scores. SCHWARZ PHARMA plans for regulatory submission during the second half of 2007